Related Experiment Video
Updated: Dec 3, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report
Eva Van Bos1, Peter Dekuyper2, Charlotte Gabriel3
1Department of Urology, AZ Maria Middelares, Buitenring-Sint-Denijs 30, 9000, Ghent, Belgium. eva.vanbos@azmmsj.be.
Background:
Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy.
Case Presentation:
This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy.
Conclusion:
Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.
